THIS is an appropriate time to review progress in the area of adrenergic receptors, particularly in terms of research that aims at achieving an understanding of these proteins at the level of their molecular composition. The past decade has seen an explosion in the field of adrenergic receptor pharmacology, made possible to a large extent by the development of the radioligand-binding assay. Alterations in receptor number and affinity occurring under a variety of physiological conditions have now been documented. Numerous examples can be given, such as an increase in receptor number in hyperthyroidism (Williams et al., 1977; Tsai and Chen, 1978) , decreased receptor number in hypothyroidism (Ciaraldi and Marinetti, 1975 ; Banerjee and Kung, 1977) or alterations in receptor-effector coupling seen in cases of abnormal thyroid hormone (Stiles and Lefkowitz, 1981) or steroid hormone levels (Davies et al., 1981) . It is not often, however, that such studies can clearly define the mechanisms underlying the observed phenomena. In the simplest case, the receptor assay may pinpoint whether an observed alteration in the physiological response occurs at the receptor level or distal to it. In a few cases, unambiguous results indicate that the altered responsiveness to an adrenergic agonist is not at the receptor level. For example, a marked hyporesponsiveness to adrenergic agonists is apparent in the neonatal dog, despite the greater numbers of receptors, an unaltered affinity, and enhanced cyclase activation, as compared to the adult (Rockson et al., 1981) . Less commonly, insights into underlying mechanisms can be gained. One of the best examples is the process of receptor desensitization, whereby the physiological response becomes attenuated on continuous exposure to an agonist (Harden, 1983) . Not only has a loss of receptors from the cell surface been documented due to an apparent internalization of these receptors in some systems, but also an actual uncoupling of the receptor from its effector system, adenylate cyclase, has been observed as an early event in certain models. Application of the radioligandbinding assay to this problem has indicated that desensitization may be effected by different mechanisms, depending on the species and tissue type examined, or even through a combination of mechanisms. However, it is clear that a definitive understanding of how various components produce a transmembrane message, of the factors modulating or attenuating this activation, and of the stoichiometry of the interactive components will come only from their purification and reconstitution into artificial membrane systems.
a-Adrenergic Receptors a-Adrenergic receptors are integral membrane proteins that, like other membrane-bound receptors, probably span the lipid bilayer. Much like 0-adrenergic receptors, these receptor proteins mediate the actions of the sympathetic nervous system following interaction with endogenous catecholamines, norepinephrine and epinephrine (Mayer, 1980; Graham, 1981) . Both a-and (3-adrenergic receptors bind the endogenous catechols with comparable affinity. However, they are readily distinguished by their differing effector-coupled responses, by the opposing effects that they mediate in different tissues, and by their affinities for synthetic ligands, which can differ by as much as one million-fold (Graham, 1981) . Further, whereas a-and /?-adrenergic receptors have a number of similar biophysical and biochemical properties, as will be detailed below, there is now ample evidence to indicate that they are distinct proteins. 636 mediate responses such as vasoconstriction, there exist prejunctional (a 2 ) receptors (Langer, 1974) . At the time of their classification, these prejunctional receptors were believed to modulate the release of norepinephrine from sympathetic nerve terminals by a negative feedback mechanism, although this conclusion at present is still controversial (McGrath, 1982; Kalsner, 1984) . Subsequently, the availability of subtype selective compounds allowed the now widely accepted subdivision of a-adrenergic receptors to be made on the basis of their differential selectivity for a variety of adrenergic agonists and antagonists ( Berthelson and Pettinger, 1977; McGrath, 1982 ; Bylund and UTrichard, 1983) .
Apart from prejunctional a2-adrenergic receptors, there now is a large body of data implicating the existence of a postjunctional a-receptor, which can be activated by « 2 -agonists to produce pressor responses in pithed animals and which is blocked by specific a2-adrenergic antagonists such as yohimbine but not by «i-antagonists, such as prazosin van Zweiten, 1981, 1982; McGrath, 1982 McGrath, , 1983 . That this postjunctional a 2 -receptor also mediates vasoconstriction was first clearly demonstrated by Drew and Whiting (1979) , when they reported that prazosin did not antagonize pressor responses to norepinephrine to the same degree as it attenuated responses to the ai-adrenergic agonist, phenylephrine. Similarly, Jauering et al. (1978) found that norepinephrine responses in isolated human digital arteries, unlike visceral arteries, were resistant to blockade by prazosin. More recently, in vivo studies in the dog (Shepperson et al., 1982; Holtz et al., 1982) and in man (Van Brummelen et al., 1983; Elliot et al., 1983) support the existence of postjunctional a 2 -adrenergic receptors.
Of particular interest is the finding that the combination of the selective a 2 -antagonist, rauwolscine, plus the ai-antagonist, prazosin, causes a greater shift of the norepinephrine vasoconstrictor doseresponse curve to the right than is produced by the same dose of either antagonist alone (Alabster and Davey, 1984) . This synergism implies that endogenous norepinephrine can interact with «i-or a 2 -adrenergic receptors and still elicit a partial biological effect, even after selective blockade of the alternate subtype. Analysis of such dose-response curves further indicates that «i-and a 2 -antagonists produce differential shifts of the curves. Rauwolscine has a greater effect on vasoconstrictor responses to lower concentrations of norepinephrine, whereas prazosin preferentially shifts the top part of the norepinephrine dose-response curve. These findings suggest that a 2 -adrenergic receptors mediate vasoconstriction to blood-borne catecholamines at physiologically relevant concentrations. In contrast, vascular a-i-adrenergic receptors may be involved primarily in sympathetic neurotransmission mediated via norepinephrine, independent of the local environment (Alabster and Davey, 1984) .
In addition to these differences, «i-and a2-adre- 56, No. 5, May 1985 nergic receptors appear to have divergent tissue distributions and functions (Graham, 1981, 1984; Bylund and UTrichard, 1983) , as well as distinct biochemical effector mechanisms (vide infra). Based largely on pharmacological studies, particularly in vascular tissue preparations, a number of other contrasting features of ot\-and a 2 -adrenergic receptors have been noted that probably reflect differences in the receptor-coupled effector mechanisms or in the triggering of signal transduction by various agents, e.g., partial vs. full agonists. For example, the time course of « 2 -adrenergic receptor-mediated pressor responses is generally slower in onset than that mediated by «i -adrenergic receptors, a difference that cannot be readily dismissed due to solubility, diffusion, etc. (Docherty and McGrath, 1980) . Other documented differences are the susceptibility of some «i-adrenergic receptors (e.g., rat anococcygeus and vas deferens but not vascular postjunctional a\ effects), and of some a 2 -adrenergic effects (vascular postjunctional a 2 effects but not prejunctional a 2 effects) to calcium entry blockade or to the absence of extracellular calcium (McGrath, 1983) . In contrast, both «i-and a 2 -adrenergic responses to nonphenylethanolamines, which are partial agonists (e.g., clonidine, xylazine, azepexole), are attenuated by calcium entry blockers, whereas those to phenylethanolamines, which are full agonists, are not (McGrath, 1983) . Such differences, the ability of pH changes and calcium entry blockers to distinguish separate components of ot\-and a 2 -mediated responses (McGrath, 1983 ), and differences in the structure-activity requirements of ai-adrenergic receptors for phenylethylamines and imidazolines (Ruffolo et al., 1983) , have suggested subtypes of a-adrenergic receptors beyond the present ai and a 2 subdivision. A third or 7 subtype of a-adrenergic receptor has been proposed ( Hirst and Neild, 1981; Bevan, 1984) , predicated on the finding that norepinephrine released after sympathetic nerve stimulation initiates membrane depolarization (excitatory junctional potentials) that is resistant to blockade by a-adrenergic antagonists. At present, however, the evidence implicating an additional subdivision of a-adrenergic receptors is largely inferential, and may be due to nuances of the particular tissue studied or to artifacts of the preparation (McGrath, 1983; Bevan, 1984) .
Biochemical Mechanisms of Signal Transduction

a^-Adrenergic Receptors
Although the mechanism(s) of signal transduction after ct\ -adrenergic receptor activation remains elusive, recent studies have provided significant new insights (Fig. 1) . In contrast to /3-adrenergic and a 2 -adrenergic receptors, which are coupled to the membrane-bound enzyme adenylate cyclase by guanine nucleotide regulatory proteins, activation of a\-adrenergic receptors does not alter intracellular levels of cyclic adenosine 3', Rather, the mobilization of Ca ++ from intracellular vesicles and/or the influx of extracellular Ca ++ appears to be linked closely to activation of the a\-receptor, as well as other calcium-mobilizing receptors, such as acetylcholine (muscarinic), vasopressin, angiotensin II, dopamine (D 2 ), histamine (H]), thromboxane, thrombin, platelet-activating factor, and various chemoattractant and growth factor receptors. This change in intracellular Ca ++ may be a primary biochemical mechanism in signal transduction, or may be secondary to the degradation of membrane phospholipids.
Initially, a phospholipid mechanism for signal transduction of calcium-mobilizing receptors was believed to involve the phosphodiesteratic cleavage of the membrane-bound phospholipid, phosphatidylinositol (PI), to yield diacylglycerol and a mixture of inositol l:2-cyclic phosphate and inositol-1-phosphate (IP) (Michell, 1975) . These compounds may increase intracellular Ca ++ by an ionophore-like action. More recently, Berridge (1983) and, subsequently, Streb et al. (1983) and Joseph et al. (1984) , have provided plausible evidence that activation of calcium-mobilizing receptors results in the breakdown of the polyphosphoinositide, phosphatidylinositol-4,5-bisphosphate (PIP2) to release diacylglycerol and myo-inositol-l,4,5-trisphosphate (IP3). Furthermore, IP 3 can selectively release Ca ++ from nonmitochondrial vesicular stores [possibly endoplasmic reticulum (Joseph, 1984) ]. On the basis of these observations, and the finding of appropriate temporal changes in IP 3 , and considerations of the IP 3 -induced Ca ++ changes with respect to its kinetics, concentration-response, and specificity, several reports have postulated that IP 3 is the second messenger for the ai-adrenergic (Joseph et al., 1984) and other calcium-mobilizing receptors (Streb et al., 1983) .
There now have been similar findings with various types of cells, including insulin-and prolactinsecreting tumor cells, neutrophils, and vascular smooth muscle cells [for a review, see Joseph (1984) ], as well as with the hepatocyte, pancreatic islet cell, and blow-fly salivary gland used in the studies mentioned above (Berridge, 1983; Streb et al., 1983; Joseph et al., 1984) . Nevertheless, at least in rat hepatocytes, Kunos (1984) has questioned the role of IP 3 as a mediator of intracellular Ca ++ release, because the breakdown of PIP 2 to IP 3 depends on extracellular Ca ++ and requires a much higher concentration of agonist than is required for increases in phosphorylase activity or calcium release (Rhodes et al., 1983) .
The enzymes involved in the PI-IP 3 cascade have not yet been clearly identified. Of particular interest is the enzyme catalyzing the hydrolysis of PIP 2 to IP 3 , presumably a PIP 2 -specific membrane-bound phosphodiesterase. Phospholipase C, a cytosolic enzyme, was initially thought to be an unlikely candidate for this reaction, as it is not membrane-bound and requires Ca ++ for activation. However, Hoffmann et al. (1982) recently reported the isolation of two distinct Pi-specific phospholipase C enzymes, one of which specifically hydrolyzed only PIP and PIP 2 after Ca ++ depletion with EGTA. This finding suggests that cleavage of PIP and PIP 2 occurs prior to increases in Ca ++ (Majerus et al., 1984) . Further, once intracellular Ca ++ rises, PI breakdown by the Ca ++ -dependent phospholipase C may predominate, since PI is quantitatively the major potential substrate for this enzyme. A predominantly membrane-bound and Mg ++ -dependent phosphatase, specific for IP 3 , has more recently been isolated from rat liver (Joseph, 1984) . This enzyme presumably 638 catalyzes the degradation of IP 3 to IP 2 , and may explain the observation that, following the rapid phase of IP 3 -induced Ca ++ release, there is a gradual reuptake of the divalent cation (Joseph, 1983) . Thus, as would be expected for a "second messenger," the cell appears to possess enzymes capable of promoting both the production of IP 3 and its degradation to IP 2 and phosphate.
Another recent suggestion by several groups is that the mechanism of signal transduction for aiadrenergic receptors may involve more than one pathway 0oseph, 1983; Corvera and Garcia-Sainz, 1983; Bodnar et al., 1983; Morgan et al., 1983) . In certain situations, responses to ai-adrenergic agonists can be clearly dissociated from those of other Ca ++ -mobilizing hormones, such as vasopressin and angiotensin II (Garcia- . For example, in the isolated hepatocyte, the phorbol ester, 12-O-tetradecanoyl-phorbol-13-acetate (TPA) can attenuate the metabolic effects of ai-adrenergic agonists without altering the responses to vasopressin or angiotensin II (Corvera and Garcia-Sainz, 1984) .
The phorbol-ester, TPA, a diterpene tumor-promoting agent, activates the Ca ++ and phospholipiddependent enzyme "C-kinase," in vitro. This activation is believed to reflect the structural similarily between TPA and diacylglycerol (Nishizuka, 1984) , which bind specifically and with high affinity to the enzyme. Diacylglycerol, as discussed above, is produced by the hydrolysis of PIP 2 and is felt to be the endogenous activator of C-kinase. This enzyme phosphorylates protein substrates at seryl and threonyl residues. As the covalent modification of proteins by phosphorylation is a common mechanism for their inactivation, it is likely that the selective attenuation of ai-adrenergic responses by TPA (Corvera and Garcia-Sainz, 1984 ) is due to C-kinaseinduced phosphorylation of a protein very proximal in the signal transduction pathway. Furthermore, as TPA stimulates the phosphorylation of insulin and somatomedin C receptors (Jacobs et al., 1983) , the «i-receptor protein may, itself, be phosphorylated by TPA.
At least two major mechanisms for signal transduction may, therefore, be operative. Initially, IP 3 is formed rapidly and leads to Ca ++ mobilization. This response is probably common to all calcium-mobilizing receptors. Subsequently, with the availability of increased Ca ++ , as well as diacylglycerol, protein kinase C may be activated and selectively limit aiadrenergic receptor-mediated responses.
Increased production of cyclic guanosine monophosphate (cGMP) has also been proposed as a mediator of ai-receptor responses. However, the role of cGMP, as well as the mechanism which increases the level of this cyclic nucleotide, is still not clearly understood. Ca ++ directly stimulates guanylate cyclase, although arachidonic acid peroxide and prostaglandin endoperoxide are more Circulation Research/Vo/. 56, No. 5, May 1985 likely to be the in vivo activators of this enzyme (Graff et al., 1978) . Haslam et al. (1980) have suggested that cGMP may act as a negative messenger, as sodium nitroprusside, a potent vasodilator and platelet inhibitor, induces cGMP formation. Similarly, Schultz et al. (1977) have demonstrated that both sodium nitroprusside and the cGMP analog, 8-bromo-cGMP, cause smooth muscle relaxation, although a-adrenergic and muscarinic agonist-induced contraction is associated with enhanced levels of cGMP, as well as inositol phospholipid breakdown. Nishizuka (1984) has interpreted these findings to indicate that, in those cells where cGMP generation inhibits the transmission of "positive signals," cAMP and cGMP do not act antagonistically, but similarly inhibit receptor-induced degradation of inositol phospholipids and thereby act as a control mechanism to limit the "positive" or vasoconstrictor stimulus.
Whether the «i-adrenergic receptor is coupled to its signal transduction mechanism by a guanine nucleotide-binding protein is presently unclear. Hoffman et al. (1980a) reported that guanine nucleotides decrease the ability of epinephrine to compete with the binding of [ 3 H]dihydroergocryptine to hepatic membrane a-adrenergic receptor sites. However, they interpreted this finding to indicate a nucleotide effect on the interaction of epinephrinenot with ai-adrenergic receptors-but with the small population of hepatic membrane a 2 -adrenergic receptors (Hoffman et al., 1980b; Geynet et al., 1981) . In contrast, some evidence suggests, as would be expected for a receptor coupled to a guanine nucleotide regulatory protein, that guanine nucleotides decrease the binding of both [ (El-Rafai et al., 1979; Geynet et al., 1980 Geynet et al., , 1981 . Goodhardt et al. (1982) have also demonstrated agonist-specific regulation by guanine nucleotides in studies with the selective a i -antagonist, [ 3 H]prazosin. The reason for these discrepant findings is not readily apparent. Nevertheless, it is of interest that a guanine nucleotide-binding protein has been implicated in the gating of Ca ++ by receptors (Gomperts, 1983) . Preliminary studies by Haslam and Davidson (1984) also suggest a role for guanine nucleotide-binding proteins in the activation of platelets by thrombin. Thus, guanine nucleotide-binding proteins, including Gj (vide infra) or perhaps G o , the newest member of the "family" described very recently by Sternweiss (1984) , may well be involved in the signal transduction pathways for the ai-adrenergic and other Ca ++ -mobilizing receptors.
a 2 -Adrenergic Receptors
Activation of a 2 -adrenergic receptors, such as muscarinic receptors in the heart (Watanabe et al., 1978; Jakobs et al., 1979) and opiate receptors in neuroblastoma-glioma (NG 108-15) cultured cells (Sharma et al., 1977) , inhibits the stimulation of adenylate cyclase and limits the availability of intracellular cAMP (Burns and Langley, 1975; Jacobs et al., 1976; Aktories et al., 1979; Cooper et al., 1979; Katada and Ui, 1981) (Fig. 1) . Binding of ligands to a 2 -adrenergic receptors and, in some tissues, responses to « 2 -agonists, correlate with this inhibitory activity (Jacobs et al., 1976) . Thus, like /3-adrenergic ( Fig. 1 ) and other cAMP-dependent receptors, such as those for dopamine (Di or D 2 ), histamine (Hi), ACTH, and prostaglandin E 2 , signal transfer for a 2 -adrenergic receptors may involve agonist-induced coupling to adenylate cyclase by a guanine nucleotide-binding protein. Additionally, GTP is required for a 2 -agonist-induced inhibition of adenylate cyclase, GTP decreases the affinity for agonists at « 2 -adrenergic receptors, and regulation of receptor affinity by guanine nucleotides correlates with agonist efficacy in modulating catalytic activity 0akobs, 1979) .
Homey and Graham/Adrenergic Receptors
Despite these similarities, it is now clear that the coupling protein for a 2 -adrenergic receptors, Gj, is distinct from that for adenylate cyclase-stimulating receptors, G s (Yamamura et al., 1977; Cooper et al., 1979; Pinkett et al., 1980; Schlegel et al., 1980; Michel et al., 1981a; Smith and Limbird, 1982; Bokoch et al., 1984; Katada et al., 1984a Katada et al., , 1984b Katada et al., , 1984c . G s and Gj are both multisubunit proteins with two common subunits, /3 (mol wt = 35,000) and y (mol wt = 8,000). However, the molecular weights of the a-subunits differ: 45,000 daltons for G s and 41,000 for Gj. Furthermore, the «-subunit of G s (G s a) is a substrate for ADP-ribosylation by cholera enterotoxin, whereas Gj a is a substrate for ADP-ribosylation by islet-activating protein, a toxin secreted by Bordetella pertussis that eliminates or at least reduces the attenuating effects of a 2 -adrenergic agonists on adenylate cyclase activity.
Details of this a 2 -agonist-induced attenuation of adenylate cyclase remain unclear. However, Gilman (1984) has presented plausible evidence to implicate the following scheme. Activation of G s -coupled receptors leads to a dissociation of the a and /3 subunit complex of G s . In the absence of Gj-coupled receptor activation, G s a is available to stimulate adenylate cyclase. However, when Gj-coupled receptors are activated, the a-and /3-subunit complex of Gj dissociates. Since the concentration of G, is greatly in excess of G s , the homologous 35,000 dalton /3-subunit of Gj released by this process prevents G 5 ainduced stimulation of adenylate cyclase by binding and thus inactivating G s a. According to this scheme, Gj a is a "passive bystander," acting as an antiinhibitor of adenylate cyclase. It is also possible that Gj a plays an active role in the regulation of other a-adrenergic functions, just as guanine nucleotidebinding proteins have roles independent of an interaction with adenylate cyclase. For example, it has been suggested that insulin affects a plasma membrane kinase and cAMP phosphodiesterase through 639 a specific guanine nucleotide regulatory protein (Heyworth et al., 1983a (Heyworth et al., , 1983b . A particularly interesting system which also involves a guanine nucleotide-binding regulatory protein, termed transducin (Tc), is visual transduction. Upon absorption of light by the visual pigment of the retina, rhodopsin, which is embedded in specialized membrane regions of the photoreceptor, Tc (like G s and Gj) exchanges GTP for GDP. The Tc-GTP complex thus formed activates a cGMP phosphodiesterase that, in turn, mediates the hydrolysis of cGMP (Fung et al., 1981; Baehr et al., 1982; Bitensky et al., 1978) . Marked similarities have also been noted between the gene products of the ras gene, contained in a significant proportion of human tumor cell lines and chemically induced rodent tumors, and the guanine nucleotide-binding proteins responsible for inhibition and stimulation of adenylate cyclase (Newbold, 1984) .
Such considerations call into question the possibility that not all « 2 -adrenergic responses are mediated by inhibition of adenylate cyclase activity. Connolly and Limbird (1983) , for example, have postulated that the effects of epinephrine on platelet function may result from the modulation of a Na + -sensitive process, independent of the a 2 -adrenergic receptor-adenylate cyclase system. Similarly, Ullrich and Wollheim (1984) have provided evidence that epinephrine inhibits insulin release from intact isolated rat pancreatic islet cells, at a step distal to the generation of cAMP. Finally, with respect to the classical a 2 -adrenergic receptor of prejunctional sympathetic terminals, there is as yet no evidence to show that inhibition of adenylate cyclase decreases norepinephrine release. Electrophysiologically, stimulation of prejunctional «2-receptors leads to hyperpolarization (Svensson et al., 1975; Taokimasa et al., 1981) , a response that may be mediated by activation of the sodium pump, i.e., Na + ,K + -ATPase, which would result in enhanced calcium efflux (Cohen et al., 1980) , thereby limiting Ca ++ availability for excitation-secretion coupling.
Solubilization, Purification and Biophysical Characterization oti-Adrenergic Receptors
To date, most studies directed at the solubilization and molecular characterization of the a t -adrenergic receptor have employed rat hepatic plasma membranes. This tissue is particularly suitable for such studies because membranes can be obtained in highly purified form and the specific activity of hepatic «i-adrenergic receptors is about 10-fold higher than in most other tissues. Also, ai-adrenergic receptors are the predominant subtype in hepatic membranes, being about four times more abundant than « 2 -adrenergic receptors.
Initial attempts to characterize the binding of solubilized rat hepatic a\ -adrenergic receptors with the (U'Prichard, 1981) , this radioligand also interacts covalently with a number of other monoaminergic receptors such as « 2 -adrenergic (U'Prichard, 1981), muscarinic cholinergic (Blazso and Minker, 1980) , opiate (Robson and Kosterlitz, 1979) , and dopaminergic receptors ( Lehmann and Langer, 1981) , as well as with nonspecific plasma membrane sites (Kunos et al., 1983) . It has been suggested that the specificity of [ 3 H]phenoxybenzamine can be enhanced by using very low concentrations of the radioligand (Kunos, 1984) . However, identification of the extremely low concentrations of receptor sites present in most tissues then becomes problematic, given the relatively low specific activity (3.3-45 Ci/mmol) of this radioligand. An additional problem with the use of [ 3 H]phenoxybenzamine is that prelabeling of membrane receptors before solubilization precludes investigations of the binding characteristics of the solubilized protein, as its binding site has been irreversibly occupied by the radioprobe. Other investigators, therefore, have attempted to solubilize the membrane-bound receptor in active form. Graham et al. (1982a Graham et al. ( , 1982b ) investigated a number of both ionic and non-ionic detergents, using a variety of solubilization protocols and various detergent-to-protein ratios. Only the non-ionic detergent, digitonin, reproducibly released the membranebound receptors in a form that could be identified by a direct radioligand-binding assay. The binding characteristics of the digitonin-solubilized preparation were identical to that of hepatic membranes, and the binding of the a\ -selective radioligand [ 3 H]prazosin was of high affinity and saturable. When the specificity of pHJprazosin binding to the solubilized preparation was examined in competition studies with a variety of adrenergic ligands, affinities comparable to those determined with particulate preparations were observed, and the stereoisomeric potency ratio of agonists was closely maintained. These findings thus indicate that the a\-adrenergic receptor-binding site of hepatic membranes can be solubilized with complete retention of its binding characteristics.
Digitonin has subsequently been used to solubilize membrane-bound a t -adrenergic receptors from a Circulation Research/Vo/. 56, No. 5, May 1985 variety of tissues and species, e.g., rat kidney and rabbit liver (Schwarz, Homey, and Graham, unpublished observations) . In addition, Wikberg et al. (1983) have since reported the successful solubilization of rat hepatic «i-adrenergic receptors with digitonin.
With the ability to solubilize the «i-adrenergic receptor in active form, its purification (70,000-fold) to apparent homogeneity (Fig. 2 ) has been achieved with sequential affinity and gel filtration chromatography (Graham et al., 1982b) . The affinity step of this procedure required the synthesis of a novel analog of the highly selective «i -adrenergic antagonist, prazosin, that could be immobilized on a solidphase support.
Biophysical characterization of the purified receptor-protein has been confined to the evaluation of the receptor-protein detergent complex, as the hydrodynamic properties of digitonin preclude determination of protein-detergent stoichiometry. Nevertheless, the Stokes radius, sedimentation coefficient, and frictional ratio of the purified receptor-protein have been determined (Graham et al., 1982b) . The values determined from these studies differ from those of the solubilized [ 3 H]phenoxybenzaminebinding protein reported by Guellaen et al. (1979) . This difference may relate to the limitations of receptor identification by [ 3 H]phenoxybenzamine-labeling, discussed above, as well as to the divergent physical properties of the different detergents used in these studies, namely, Lubrol PX (Guellaen et al., 1979) vs. digitonin (Graham et al., 1982b) .
The subunit characteristics of the «i -adrenergic receptor have been investigated after ^HJphenoxy-benzamine labeling of the membrane receptor (Guellaen et al., 1982; Kunos et al., 1983) , after purification (Graham et al., 1982b) , and, more recently, after covalent labeling of membranes with high specific activity, selective photoaffinity ct\-probes (Seidman et al., 1984a (Seidman et al., , 1984b Fredrik-LeebLundberg et al., 1984) . Subunit molecular weights (MW) were determined from gel electrophoresis studies. Guellaen et al. (1982) Seidman et al. (1984a Seidman et al. ( , 1984b ) identified a subunit of approximately 80,000 daltons, as well as a 58,000-59,000 dalton species, in membrane preparations (Fig. 2) . From these studies, therefore, there appears to be general agreement that the «i-adrenergic receptor from rat hepatic membranes, as well as other tissues (Fredrik-Leeb-Lundberg et al., 1984) , contains a major subunit of approximately 80,000 daltons. The smaller 59,000 dalton peptide, which retains hormone-binding activity (Graham et al., 1982b) , may be a proteolytic fragment. However, the possibility that this species is an integral part of the «i-adrenergic receptor or is generated in vivo in the intact plasma membrane cannot be entirely excluded, as Seidman et al. (1984b) and Kunos (1984) were unable to prevent completely the identification of a 58,000-59,000 dalton protein, despite the use of the most stringent measures to prevent proteolysis. Since a molecular weight of 147,000-160,000 daltons has been reported for the holoreceptor (Graham et al., 1982b; Venter et al., 1984) , it is probable that the «i-adrenergic receptor contains more than one subunit.
Studies with the purified rat hepatic ai-adrenergic receptor-protein indicate a resilient tertiary structure stabilized by a disulfide bond. This bond is critical Seidman et al. (1984a) PAGE and autoradiography (lnsoft, 1984) . Rashidbaigi et al. (1983) for ligand binding but is inaccessible to solvent. Thus, complete binding activity can be recovered after lyophilization of the receptor-protein and renaturation out of guanidine (Graham et al., 1982a (Graham et al., , 1982b Homey et al., 1982) . Strong hydrophobic interactions are also likely, since full binding activity can be observed with urea solubilization (Homey et al., 1982) . The canine lung ft-adrenergic receptor is similarly stabilized by hydrophobic interactions ( Homey and Sylvestre, 1982) , although the binding site of both the membrane and purified forms of this receptor-protein contains a disulfide bond accessible to solvent (Homey et al., 1982) . Preliminary studies by Snavely and Insel (1983) suggest that aiadrenergic receptor sites of rat renal membranes may also contain sulfhydryl groups critical for ligand binding. Studies directed at the solubilization and molecular characterization of « 2 -adrenergic receptors have employed platelets, almost exclusively, as the tissue source. Smith and Limbird (1981) and Michel et al. (1981b) have solubilized platelet membranes with the non-ionic detergent, digitonin, which has permitted the identification of the receptor-protein by direct radioligand-binding assay. The digitonin-solubilized binding component could be identified with the a 2 -selective antagonist, [ 3 H]yohimbine. Although the binding characteristics of the solubilized receptor were largely conserved with respect to the membrane-binding site, the affinity for agonists was reduced, and was no longer modulated by guanine nucleotides. In addition, solubilization of the platelet membranes after prelabeling with the agonist [ 3 H]epinephrine resulted in a complex sensitive to guanine nucleotides that sedimented more rapidly in sucrose gradients than unoccupied or antagonistoccupied receptors. These findings suggest that agonist occupancy stabilizes the receptor interaction with the inhibitory guanine nucleotide-binding regulatory protein, which is required for modulation of agonist affinity by guanine nucleotides. Thus, in the absence of agonist occupancy, solubilization presumably promotes an uncoupling of the membrane receptor from its effector-coupled component, and agonist affinity is no longer modulated by guanine nucleotides. These studies also provide some data on the biophysical properties of the a 2 -adrenergic receptor. Thus, a sedimentation coefficient of 11.4-12.9S was observed for the unoccupied or antagonist-labeled receptor, and 13.4-14.6S for the agonist-prelabeled protein (Smith and Limbird, 1981; Michel et al., 1981b) .
Major bands at 67,000 and 53,000 daltons are visualized. Lanes 5 and 6: S49 lymphoma membrane f) 2 -adrenergic receptors were labeled with n5 l-azidobenylpindolol in the absence (lane 5) or presence (lane 6) of alprenolol (10~6 M). The autoradiogram shows specifically labeled peptides at 65,000 and 55,000 daltons. [Reproduced from
Partial purification of the digitonin-solubilized platelet a 2 -adrenergic receptor has been reported. Smith and Limbird (1982) employed a wheat germ affinity resin, which successfully adsorbed the solubilized receptor. This finding provides evidence for the glycosylated nature of the protein, although cosolubilization of an unrelated but glycosylated protein in the same detergent micelle cannot be definitely excluded. Desorption was achieved with the carbohydrate N-acetyl-O-glucosamine. Regan et al. (1982 Regan et al. ( , 1984 have reported a 200-to 600-fold purification of the human platelet « 2 -adrenergic receptor by the use of an affinity column composed of a 3-benzazepine (SKF-101253) coupled to Sepharose CL-4B. However, the specificity of the protein purified with this affinity resin is not entirely clear. Thus, phentolamine, a nonselective a-adrenergic antagonist, was equal to yohimbine, an « 2 -antagonist, in its ability to prevent adsorption of the solubilized receptor protein to the affinity resin, and was more effective than yohimbine in eluting the adsorbed protein from the column. The use of this affinity column for purification of « 2 -adrenergic receptors from tissues containing both a-receptor subtypes may also be limited, as SKF-101253 has a relatively low selectivity (5-fold) for a 2 -compared to «i-adrenergic receptors.* * With a demethylated analog of the selective a 2 -adrenergic antagonist yohimbine coupled to agarose (Graham et al., 1982c), partial purification (200-fold) of the digitonin-solubilized platelet-membrane receptor has also been achieved (Graham, Karnes, and Homey, unpublished 
observations).
Circulation Research/Vol. 56, No. 5, May 1985 After partial affinity purification of solubilized platelets, Regan et al. (1984) covalently labeled the proteins obtained with the alkylating agent [ 3 H]-phenoxybenzamine. The molecular mass of the labeled proteins then was evaluated by sodium dodecyl sulfate gel electrophoresis and autoradiography and was found to be 61,000 daltons. In contrast, Venter et al. (1983) used target-size analysis by radiation inactivation to determine a molecular mass of 160,000 daltons for the holoreceptor in platelet membranes. Atlas and Steer (1982) recently reported the synthesis and characterization of an affinity label, clonidine p-isothiocyanate, for the « 2 -adrenergic receptor. Although this compound and a related radiolabeled photoaffinity probe (U' Prichard and Ensberger, 1983) have low affinity for the a 2 -adrenergic receptor, it can be anticipated that related high affinity, high specific activity compounds will soon be available for more complete investigation of the molecular characteristics of this adrenergic receptor subtype.
Progress in /3-Receptor Purification and Reconstitution
The /8-adrenergic receptor is also an intrinsic membrane protein which requires detergents for its solubilization. When liberated into a detergent micelle, these molecules can be characterized and purified by biochemical techniques, including gel filtration and affinity chromatography. Haga et al. (1977) prelabeled the receptor with I-hydroxybenzylpindolol before solubilization, thus allowing them to characterize the biophysical properties of the labeled receptor-detergent complex. However, such a technique is cumbersome, particularly in the presence of high levels of nonspecific ligand binding. Furthermore, a prelabeling technique does not permit the use of purification methods such as affinity chromatography which requires an unencumbered binding site to allow the receptor to interact with immobilized ligand. Although high concentrations of disrupting agents such as urea have been shown to liberate the receptor (Homey and Sylvestre, 1982) , digitonin, a sterol detergent similar to the bile acids, remains the most useful and effective agent for its solubilization. It appears to be the only non-ionic detergent that does not appreciably interfere with ligand binding (Caron and Lefkowitz, 1976) . Problems with characterization of the solubilized receptor relate to the extremely low concentration of the receptor, typically 50 to 400 fmol/mg of membrane protein, or 1,000 to 10,000 copies/cell, usually in direct relation to cell surface area. After solubilization, concentrations in the pmol (10~1 2 M) range can be expected. This, together with the relatively high level of nonspecific binding of lipophilic ligands such as dihydroalprenolol, has made routine assay difficult. Successful solubilization of the /?-receptor in a form assayable by direct binding assay Homey and Gra/iam/Adrenergic Receptors was reported by Caron and Lefkowitz (1976) . The solubilized receptor was extracted from frog erythrocyte membranes. These membranes could be readily prepared, and contained a receptor concentration as high as 1 pmol/mg (Caron and Lefkowitz, 1976) . With the development of reliable solubilization and assay techniques, purification of the receptor protein became an attainable goal, although the task remained onerous. Two different affinity supports employing either alprenolol (Vacquelin et al., 1977; Shorr et al., 1981) or acebutolol (Homey et al., 1983) have proved invaluable in isolating the solubilized receptor. Recently, this technique, coupled with high performance gel filtration chromatography, has enabled the entire purification protocol to be completed within a period of hours rather than days.
A perplexing observation was the initial description by several laboratories of multiple molecular weight forms, whether the receptor was identified by SDS gel electrophoresis after purification, or, for impure preparations, by the technique of photoaffinity labeling. It is valuable to review some of this data and then summarize the relevant points.
The initial studies which were successful in purifying the /3-receptor used either avian or amphibian erythrocytes. These are nucleated and provide a rich source of receptors with concentrations as high as 1 pmol/mg membrane protein. Purification of the turkey erythrocyte /3-receptor was first reported by Vacquelin et al. in 1977 . Subsequently, Atlas and Levitzki (1978) , utilizing a tritiated affinity label, a derivative of propranolol, visualized two bands of 37,000 and 41,000 daltons for the /^-receptor of the turkey erythrocyte. For the /3 2 -receptor of the frog red blood cell, the laboratories of Caron and Lefkowitz have consistently reported a molecular weight for the hormone-binding subunit of approximately 58,000 daltons, with the peptide migrating as a rather diffuse band on SDS gels (Shorr et al., 1981) . In contrast, the /3 2 -receptor from mammalian tissue, principally lung, was identified at several different weights of 64,000 , 53,000 (Homey et al., 1983) to 59,000 (Fraser and Venter, 1982) and 44,000 daltons. The affinity-purified /32-receptor from canine lung was first reported to contain a major form of approximately 53,000 daltons (Homey et al., 1983) . However, over the past 2 years, this diversity in molecular weight is slowly disappearing, and the likelihood that it is an artifact produced by proteolysis is becoming clearer. Recently, Benovic et al. (1983) have described a principal molecular weight of 64,000-67,000 daltons from mammalian lung with lesser bands sometimes seen at 53,000-55,000 daltons. Rashidbaigi et al. (1983) have consistently reported visualization of 65,000 and 55,000 dalton bands for the photolabeled /3 2 -receptor of the S49 lymphoma cell (Fig. 2) . With more careful attention to inhibiting proteolysis, as well as more rapid purification procedures, a principal band of 67,000 daltons for the /32-receptor from calf lung, with a 643 lesser band at 53,000 daltons, was also visualized ( Insoft and Homey et al., 1984) (Fig. 2) . More recently, a preliminary report describes a principal band of 67,000 daltons for the /? 2 -receptor from liver ( Graziano and Malbon et al., 1984) . For the mammalian /3i-receptor, a principal molecular weight of 62,000-67,000 daltons is generally visualized, whether obtained by photoaffinity labeling of myocardial membranes (Stiles et al., 1982) or following purification of the receptor from fat cell membranes (Cubero and Malbon, 1984) . The turkey red blood cell, identified as a ft -receptor by its relative affinities for a variety of ligands, is anomalous, with two molecular weight forms of approximately 43,000 and 38,000 daltons being reported (Atlas and Levitzki, 1978; Shorr et al., 1982; Burgermeister et al., 1982) .
In summary, both the mammalian ft-and /3 2 -receptors, whether identified following purification or by photoaffinity labeling, consist of a principal band of 62,000-67,000 daltons. In addition, several laboratories have consistently visualized lower molecular weights of approximately 53,000-55,000 daltons, particularly for the /3 2 -receptor.
Although increasing information on the molecular weight of the hormone-binding subunit has become available, the structural and chemical properties of the intact receptor have not been well characterized. For comparison, in the case of the nicotinic acetylcholine receptor, it is known that a pentameric structure exists, with each of the four subunits (a, /3, 7, and 5) (Changeux, 1981; Conti-Tronconi and Raftery, 1982) represented singly, except for the asubunit, which contributes two polypeptide chains to the pentameric ring. In the case of the /3-receptor, little information of this kind exists. Preliminary data based on hydrodynamic measurements of the intact receptor following receptor solubilization suggest that it contains the hormone-binding polypeptide in monomeric or perhaps dimeric form Cubero and Malbon, 1984) . Since the receptor is a hydrophobic protein and does not behave as a globular structure in solution, its absolute mass cannot be directly calculated by comparing its mobility to soluble protein standards during gel exclusion chromatography or sedimentation velocity experiments. However, approximations of this type have indicated that the non-denatured receptor has a molecular weight ranging from 130,000-160,000 daltons consistent with a monomeric or possibly dimeric representation of the hormone-binding polypeptide, depending on the contribution of bound detergent to this measurement of overall mass (Haga et al., 1977 (Haga et al., , 1983 Cubero and Malbon, 1984) .
Some data indicate that the receptor is a glycoprotein, such as the demonstration that the solubilized receptor can be immobilized on lectin affinity resins which are known to bind to specific carbohydrate residues (Stadel et al., 1981a) , and that expression of the receptor on the cell surface is inhibited by the 644 antibiotic tunicamycin which inhibits protein glycosylation (Doss et al., 1982) . Since it is well known that the mobility of a protein during SDS-polyacrylamide gel electrophoresis can be affected by its state of glycosylation, it is possible that the minor subunit observed at 53,000-55,000 dalton and the broad 50,000-60,000 dalton band observed in frog /3-receptor differ in carbohydrate rather than amino acid content. Differences in carbohydrate content might also contribute to the minor variations in mobility for receptor subtypes prepared from different species and cell lines (Stiles et al., 1984) . Although the migration of a protein during SDS-gel electrophoresis is not only a function of its amino acid content, i.e., molecular weight, but also of its carbohydrate composition, the above studies nevertheless suggest that the mammalian /3-adrenergic receptor consists of a single peptide of 62,000-67,000 daltons. This structure is generally observed despite the tissue of origin or the receptor subtype. In certain tissues from lower species, such as amphibian and avian erythrocytes, receptor proteins have consistently been documented to be of smaller molecular weight.
Several laboratories have now successfully incorporated these highly purified receptor preparations into lipid vesicles, thus providing a system in which individual components of hormone-sensitive adenylate cyclase can be reconstituted. Schramm and his colleagues laid the groundwork for these types of studies. They initially introduced a crude solubilized receptor preparation into membranes lacking receptor but containing Gs (the GTP-binding protein which couples receptor to adenylate cyclase) and cyclase catalytic activity Schramm, 1980, 1982) . More recently, Pederson and Ross (1982) and Brandt et al. (1983) successfully reconstituted partially purified /3-receptor from turkey erythrocytes with Gs purified from rabbit liver, resulting in both hormone-mediated stimulation of adenylate cyclase activity and GTPase activity, the latter being a direct measurement of receptor-coupled G s . Similarly Kelleher et al. (1983) reconstituted a highly purified /?-receptor prepared from turkey erythrocytes into human erythrocyte membranes which lacked both receptor and catalytic activity, but which possessed the Gs coupling protein. A GTP-induced shift in agonist affinity, which was lacking in the solubilized receptor preparation, indicated that a functional linkage between the receptor protein and Gs was occurring. Previous to this work, Jeffery et al. (1980) had demonstrated similar results utilizing a crude detergent-solubilized receptor preparation. Recently, with purified ft-receptor preparations which ran as single bands of approximately 65,000 daltons on SDS gels, Cerione et al. (1983) were able to reconstitute hormone-sensitive adenylate cyclase into erythrocytes from Xenopus laevis which contain Gs and catalytic activity, but lack endogenous receptors.
When considered together, the above studies indicate that the hormone-binding peptide contains Circulation Research/Vol. 56, No. 5, May 1985 all the necessary information to transduce a signal following the binding of an agonist hormone. Within a short period of time, it can be expected that such reconstitution experiments, utilizing purified receptor and cyclase components reconstituted within artificial lipid vesicles, will allow direct evaluation of the stoichiometry and kinetics of the reaction leading to cyclase activation following hormone binding. Furthermore, such approaches will allow definition of the role that the lipid bilayer plays in promoting and modulating these interactions.
Receptor Regulation
Much information and insight has accrued concerning the mechanisms of catecholamine-induced desensitization. Although a large body of experimental data has accumulated in this area, it is our aim to review only that work relating to the molecular mechanisms underlying these processes. We will limit the discussion to that form of desensitization, generally termed homologous, which indicates cellular refractoriness upon rechallenge with the same agonist used in the initial exposure. By way of introduction, a general scheme for catecholaminespecific desensitization can now be formulated (Harden, 1983) . The receptor proteins probably are situated within the lipid bilayer as distinct species that interact with hormones and Gs, the guanylyl nucleotide-binding protein(s), which couples the receptor protein to the catalytic unit of adenylate cyclase. Upon binding agonist, there is a rapid conversion from the native form of the receptor to one incapable of forming a high affinity complex with Gs. It is postulated, but has not been proved, that this event is due to covalent modification of the receptor protein. Thereafter, the receptor protein probably is internalized and subsequently degraded or reprocessed, according to evidence from several laboratories. Chuang and Costa (1979) were the first to suggest this possibility, utilizing the frog erythrocyte as a model system to demonstrate that [ H]-dihydroalpenolol (DHA)-binding sites appeared in the cytosol after exposure of the cells to isoproterenol. Later work suggested that a biochemical pathway similar to that mediating internalization of peptide hormone receptors might be involved; however, the details of these events still remain sketchy (Chuang, 1981) . This process of internalization has subsequently been confirmed by others who have also demonstrated that the internalized ^-receptors probably exist in a vesicular form which may eventually be degraded (Waldo et al., 1983) . The early processes of uncoupling and internalization are rapid, beginning within 1-2 minutes after binding of agonsits, and are responsible for a loss of adenylate cyclase activation, and may also explain the apparent low affinity agonist binding seen in whole cell-binding assays. It has been suggested that this latter phenomenon is secondary to internalization of uncoupled receptors, thus precluding their bind- The likelihood that each of these steps will eventually be dissected is underscored by recent work carried out by Stadel et al. (1983) . Heterologous desensitization in the turkey erythrocyte ftreceptoradenylate cyclase system previously has been shown to be mediated through a cAMP-dependent pathway (Stadel et al., 1981b) . Unlike the more common form of catecholamine-specific desensitization, which clearly does not depend on activation of cyclase catalytic activity and cannot be mimicked by agents which increase intracellular cAMP, the uncoupling of the receptor from cyclase can be produced by either of these interventions in the turkey erythrocyte. Furthermore, since receptor loss in the turkey erythrocyte does not occur, even at later stages of desensitization, the technique of photoaffinity labeling could be brought to bear to ascertain whether the hormone-binding subunit is physically altered under conditions that lead to receptor desensitization. After agonist exposure in the intact cells, the receptor was covalently labeled with [
125 I]azidobenzylcarazolol, and a shift in its apparent molecular weight was observed. Since covalent modification of a protein can alter its behavior during SDS-gel electrophoresis, it was suggested that cAMP-dependent phosphorylation of the receptor might have occurred. Thereafter, the intact cell was desensitized during incubation with 32 Pj and the receptor protein was purified by affinity chromatography. Under these conditions, 32 P| labeling of the receptor protein was detectable, and its migration on the gel coincided with that observed by photoaffinity labeling. Finally, purified cAMP-dependent protein kinase was shown to phosphorylate the purified ftreceptor protein. Rashidbaigi et al. (1983) have recently carried out similar investigations in the mammalian S49 lymphoma line. During the early stages of desensitization before receptor loss has occurred, these investigators could not detect any alteration in the mobility of the photolabeled receptor on SDS gels. This suggests that phosphorylation of the receptor, to a significant extent, is not initiated during receptor uncoupling in this system as occurs in the turkey erythrocyte.
Although the mechanism of desensitization, as outlined above for the turkey erythrocyte /3]-receptor, does not appear to be the major pathway by which receptor function is modulated by agonists in mammalian cells, this work nevertheless emphasizes the potential insight to be gained through the scrutinizing of purified components as they become available. Such an approach is not limited to this 645 kind of study, but should prove useful in demonstrating, for any particular pathophysiological state, whether an altered form of receptor protein is operative. For example, recently Vatner et al. (1984) have found, in a chronic canine model of severe left ventricular hypertrophy, that the affinity of the ft receptor protein for adrenergic ligands is significantly reduced and worsens as heart failure ensues. Since even antagonist binding demonstrates this alteration, it is possible that the receptor protein has been changed through a post-translational modification (e.g., phosphorylation) or a different gene product has been expressed consistent with gene polymorphism. Several examples of this latter mechanism clearly occur in the hypertrophied left ventricle, where isozymes of lactate dehydrogenase (LDH), myosin, and creatine phosphokinase are transcribed under these conditions.
Antibodies
The development of specific antibodies to the ft adrenergic receptor is a major goal of several laboratories, and would provide a valuable tool for investigating receptor regulation and structure. In the analysis of desensitization where receptor loss occurs as detected by ligand binding, anti-receptor antibodies not dependent on a functional binding site would allow an independent method of quantifying receptor metabolism. Homology between receptor subtypes could be addressed using antibodies to identify specific epitopes which might differ between two related polypeptides, e.g., between the ft-and j3 2 -receptors. Although several groups have now successfully raised antibodies to the ftreceptor protein, little substantive information has yet come from studies with these probes. Wrenn and Haber (1979) initially reported an antibody raised to a partially purified cardiac ft -receptor preparation which distinguished between the ft-and ft-receptor subtypes. However, it appeared to be of generally low affinity. Couraud et al. (1981) and Fraser and Venter (1980) both have reported on the development of monoclonal antibodies to the ft-adrenergic receptor of the turkey erythrocyte. However, on the basis of their titers, these antibodies were of such low affinity that their sensitivity was probably insufficient to permit them to be used successfully as probes of receptor structure or metabolism. Strader et al. (1983) also have recently obtained antisera raised to a partially purified ftreceptor preparation which noncompetitively inhibits adenylate cyclase activation.
In addition to immunizing with the receptor protein itself, binding site-directed anti-receptor antibodies have been developed by employing the anti-idiotypic response to antibodies raised to the ligand, alprenolol. Anti-alprenolol antibodies are used which display binding characteristics similar to those of the ftreceptor itself (Rockson et al., 1980) . Immunization with these antibodies generates anti-646 idiotypic antiserum that contains antibodies directed against the binding site of the first antibody. Since the anti-ligand antibodies used as the immunogen were homologous to the biological receptor in their binding properties, the second antibody response might be expected to generate a set of anti-idiotypic antibodies that interacts with a similarly structured binding site within the receptor itself. Homey et al. (1980) used this approach to generate an antisera which competitively inhibited both ligand binding and cyclase activation by isoproterenol to /3-receptors from different species and tissue types. Similar work also had been carried out by Schreiber et al. (1980) , although their antisera behaved in a somewhat anomalous manner, not clearly interacting directly with the ligand-binding site of the receptor.
Elicited polyclonal anti-idiotypic antiserum has the disadvantages that the serum response is often short-lived and that multiple antibodies of varying affinity are expressed. The development of monoclonal anti-idiotypic antibodies via somatic cell hybridization techniques should overcome these problems and permit the generation of sufficient quantities of antibody to be used routinely as laboratory reagents.
Directions for the Future
Although much progress has been made in the structural characterization of the /?-and a-adrenergic receptors, there are wide gaps in our knowledge of how these receptors are arranged in the lipid bilayer and of the exact mechanisms through which they couple to effector proteins. What are the directions that will lead in the future to a clearer picture of how these membrane proteins work? If we list recent advances in the molecular characterization of another neurotransmitter receptor, the nicotinic acetylcholine receptor (Burgermeister et al., 1982; Changeux, 1981) , then the power of the new approaches in molecular biology becomes readily apparent. Since this receptor could be found in much greater quantities, its purification in high yield was accomplished with relative ease. With large quantities of protein, monoclonal antibodies to defined epitopes were raised ( Gullick and Lindstrom, 1983) . Primary amino acid sequence data became available as well (Noda et al., 1982 (Noda et al., , 1983a (Noda et al., , 1983b . With these tools in hand, the gene was eventually isolated and the receptor has now been cloned and expressed in active form (Mishina et al., 1984) . Such tools, particularly site-specific antibodies, have allowed assignment of specific functions, e.g., ligand binding to a specific subunit of this receptor, one of four distinct polypeptide chains. Their arrangement as pentamers (the a subunit is represented twice) to form apparent pores within the membrane bilayer was determined when the purified receptor was reconstituted into synthetic phospholipid micelles. Recently, monoclonal antibodies raised to each of these subunits demonstrated that immunologically Circulation Research/Vo/. 56, No. 5, May 1985 similar regions exist within the different subunits. This, together with primary amino acid sequence data, has led to the suggestion that the subunits may have evolved from a common precursor gene through the process of reduplication.
The availability of a cDNA clone and the eventual expression of the gene product in a bacterial system would have even greater implications for progress in the area of adrenergic receptors. These proteins exist in such small quantities that experiments aimed at addressing questions related to the stoichiometry between receptor and G s , the effects of excess receptors, and the processing of the receptor protein may be more easily approached as cloning techniques allow for the expression of the receptor protein in larger quantity. Both the availability of cDNA probes and monoclonal antibodies to specific sites within the receptor subunit should allow insight into the evolution of the different adrenergic receptor genes. There is the possibility that an even greater diversity of receptor subtypes exists that could represent either gene polymorphism or allelic variation. These kinds of questions can be adequately addressed only after an appropriate cDNA probe is obtained. Furthermore, those factors, including heterologous and homologous hormonal control mechanisms which regulate expression of the receptor gene, can be studied to determine whether they mediate their effect at the transcriptional or translational level.
